CVS Health reported strong second-quarter financial results today, exceeding both earnings and revenue expectations set by analysts. The company posted adjusted earnings per share of $2.58, significantly higher than the $1.85 anticipated by the market. Total quarterly revenue reached $106.1 billion, marking a 7% increase compared to the same period last year.
The improvement is largely driven by a recovery within the Aetna insurance unit. The medical benefit ratio for this division dropped to 87.4%, down from 89.9% a year ago, signaling more effective management of medical costs relative to premiums collected. Additionally, all three of the company's major segments—insurance, pharmacy, and health services—performed better than initial forecasts.
Management raised its full-year guidance for 2026, projecting adjusted earnings between $7.90 and $8.10 per share. This is a notable increase from the previous estimate of $7.30 to $7.50. The company also expects total annual revenue to reach at least $414 billion.
Beyond financial figures, the company announced a new collaboration with Eli Lilly. Starting in the fourth quarter, eligible patients will be able to access weight management treatments, including Zepbound and Foundayo, directly through the CVS Health mobile application. This initiative supports both insured patients and those paying out of pocket.
While these results are positive, the company maintains a cautious outlook for the remainder of the year. Executives point to persistent high medical costs and wider economic challenges as factors that require careful monitoring as they execute their broader turnaround strategy.